29

2023

-

11

We: Exploring the Current Market Status and Development Prospects of China’s Bone Health Industry


I. Background of Industry Development

1. China’s population is aging at an accelerating pace, and the proportion of the population aged 65 or older is increasing year by year.

China is one of the fastest-aging populations in the world. According to insights from the We Health system, the seventh national census revealed that as of November 2020, people aged 65 and above accounted for 13.5% of China’s total population, indicating a further deepening of the aging trend. The United Nations defines a country or region as an “aged society” when the proportion of its population aged 65 and over reaches 7% or more, or when the proportion of people aged 60 and over exceeds 10% of the total population. By the UN’s standards, China entered an aged society as early as 2000.

From 2008 to 2020, the number of people aged 65 and over in China continued to rise, and their share of the total population also kept increasing. In 2020, the population aged 60 and above in China reached 264.02 million, accounting for 18.7% of the total population. Among them, the population aged 65 and above was 190.64 million, representing 13.5% of the total population. These figures clearly show that China’s population aging trend is accelerating.

2. The level of healthcare expenditure among urban and rural residents has increased somewhat.

The level of healthcare expenditure among urban and rural residents in China has increased, and its share of total consumption expenditure has been rising year by year, reflecting the growing healthcare needs of Chinese residents. An analysis of the growth in healthcare expenditure among urban and rural residents reveals that from 2007 to 2020, per capita healthcare expenditure for urban residents consistently exceeded that of rural residents, and both per capita healthcare expenditure for urban and rural residents showed a yearly increase. In 2020, the per capita healthcare expenditure for urban residents and rural residents in China was 2,172 yuan and 1,418 yuan, respectively.

Overall, in recent years—with the exception of 2020, when it declined—China's rural residents have seen an increasing share of their household expenditures allocated to healthcare, while urban residents' healthcare spending has followed a pattern of first declining and then rising. In 2020, the shares of healthcare expenditures among China's urban and rural residents were 10.34% and 8.04%, respectively.

2. Current Status of Industry Development

1. The orthopedic market is experiencing strong demand, and the number of patients receiving diagnosis and treatment has been increasing year by year.

Due to the accelerating aging population and the improved healthcare standards in both urban and rural areas, China’s orthopedic market is experiencing robust demand, with the number of patients undergoing diagnosis and treatment increasing year by year. From 2012 to 2019, the number of patients treated at Chinese orthopedic hospitals showed a fluctuating upward trend. In 2019, the number of patients reached 16,694,400, representing a 6.39% increase over 2018. Based on the per-patient cost of treatment at Chinese orthopedic hospitals and their total revenue, combined with the projected growth trend in the number of patients treated, Qianzhan estimates that the number of patients treated at Chinese orthopedic hospitals in 2020 will be approximately 17,028,300.

From 2012 to 2019, the number of hospital admissions to orthopedic hospitals in China showed an overall increase. In 2012, the number of admissions was 772,100 person-times, rising to 1,456,600 person-times by 2019—a year-on-year increase of 0.61% compared to 2018. Based on the trend in recent years of growth rates in hospital admissions to Chinese orthopedic hospitals, the estimated number of admissions for 2020 is approximately 1,471,214 person-times.

2. Supply-demand imbalance leads to year-on-year increases in orthopedic treatment costs.

The imbalance between supply and demand in the industry has led to a year-on-year increase in healthcare costs for musculoskeletal disorders among residents. Taking the average treatment cost for the most representative condition—lumbar disc herniation—as an example, per capita medical expenses rose from 8,528.0 yuan in 2013 to 10,048.0 yuan in 2019. Specifically, pharmaceutical costs have shown a downward trend, while costs for examinations, treatments, and surgeries have all been on the rise.

3. The orthopedic hospital’s revenue and expenditures have increased, and its profit levels remain relatively stable.

From 2012 to 2019, both the revenue and expenditure of orthopedic hospitals in China showed an overall upward trend, while total profits experienced fluctuations. In 2019, the total revenue of orthopedic hospitals reached 19.214 billion yuan, total expenditures amounted to 18.533 billion yuan, and total profits totaled 682 million yuan.

According to the forecast based on the revenue and expenditure growth of Chinese orthopedic hospitals, in 2020, the total revenue of orthopedic hospitals was approximately 21.5 billion yuan, total expenditures were 20.7 billion yuan, and the total profit of orthopedic hospitals was 800 million yuan.

From the perspective of the revenue structure of orthopedic hospitals, medical revenue is the primary source of income for these hospitals. In 2019, medical revenue accounted for 96.35% of total revenue, totaling 18.513 billion yuan; fiscal subsidy revenue accounted for 2.71%, amounting to 521 million yuan. Based on the growth trend of the revenue structure of Chinese orthopedic hospitals, Qianzhan forecasts that in 2020, fiscal subsidy revenue, medical revenue, and other revenue will reach 580 million yuan, 20.7 billion yuan, and 220 million yuan, respectively, with respective shares of 2.70%, 96.28%, and 1.02%.

3. Prospects for Industry Development

1. Orthopedic diseases are concentrated among people aged 45 and older.

Observation from the We Health System: Looking at the age distribution of orthopedic disease patients, the number of individuals under 14 years old affected by orthopedic conditions is relatively low. The proportion of patients aged 15 to 44 ranges between 5% and 35%. Orthopedic disease patients are predominantly concentrated among those aged 45 and older. Among these patients, more than 75%—including those with joint disorders, gout, spinal conditions, intervertebral disc disorders, osteoporosis, and bone structural abnormalities—are aged 45 or older.

2. The future trend of aging is not optimistic, and the bone disease market has vast potential.

The aging population will continue to deepen in the future, with the number of people aged 65 and above expected to exceed 300 million by 2025. According to data released by Credit Suisse in early February 2020, China is projected to enter an ultra-aged society around 2032—defined as a situation where the population aged 65 and above exceeds the population aged 10 to 25. It is estimated that the population aged 60 and above on the Chinese mainland will reach 300 million by 2025, surpass 400 million by 2033, and peak at approximately 487 million around 2050, accounting for roughly one-third of the total population at that time. Orthopedic diseases primarily affect individuals aged 45 and older; therefore, the deepening of aging will to some extent boost the development of China’s bone disease market. The outlook for China’s bone disease market in the future is exceptionally promising.

。